Ehave Announces Launch of the Next Generation of the Ehave Platform and Ehave Connect to Facilitate Rapid Third-Party Content Integration
TORONTO, Sept. 20, 2017 /CNW/ -- Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced the completion of the next generation of its flagship informatics platform. The Ehave Platform upgrade leverages the functionality found within the Ehave Platform Core and simplifies the hosting of third-party digital tools and applications for mental health, including the recently launched Conners® suite of assessments to diagnose attention deficit hyperactivity disorder ("ADHD") offered digitally by Ehave in partnership with Multi-Health Systems ("MHS"). Ehave also announced the launch of Ehave Connect, a digital "App Store" designed to enhance access to a broad array of content offered by Ehave and its growing roster of mental healthcare partners.
The Ehave Platform's flexibility allows new content to be added quickly, and supports creation of third-party content by allowing developers access to its library of clinical protocols, which includes proven cognitive assessments that can be easily embedded into new applications and digital games designed to improve the diagnosis and/or treatment of mental health conditions.
Developers and organizations that partner with Ehave to commercialize or utilize content through the Ehave Platform will benefit from Ehave's unprecedented back-end data management software, which is designed to offer a comprehensive view of a patient's mental healthcare journey. The system upgrade enables organizations to register individual users and modulate workflows to best suit the needs of clinicians and researchers. Ehave Connect currently offers a variety of assessment tools, including Ehave's proprietary MegaTeam applications.
Prateek Dwivedi, CEO of Ehave, said, "The release of this upgraded version of the Ehave Platform signals that we are moving into the next chapter for Ehave. I was recruited to Ehave with the vision to mold the Ehave Platform into an all-encompassing mental healthcare informatics solution, providing physicians and researchers both trusted and novel tools to enhance the lives of their patients. Ehave Connect provides a nimble and adaptable platform for strategic partners to seamlessly integrate content and manage data, and is a critical step towards our vision of enabling objective, data-driven decisions for mental healthcare providers from patient intake through patient outcomes verification."
Further expansion is planned for Ehave's partnership with MHS to offer digital versions of its entire catalogue of clinically validated mental health assessments through Ehave Connect. Integration is currently underway for MHS's Davidson Trauma Scale™ post-traumatic stress disorder ("PTSD") assessment suite to enable Ehave to administer an upcoming clinical trial in partnership with MedReleaf, which will evaluate the potential of medical cannabis in the treatment of patients suffering from PTSD. The Ehave Platform-powered MedReleaf branded app is designed to empower physicians and researchers with the ability to track medication adherence and patient outcomes for various cannabis-based therapeutics and dosing regimens.
About Ehave, Inc.
Ehave (Ticker: EHVVF) is empowering the mental healthcare community with a next-generation of data-rich tools designed to improve patient management, diagnosis, and treatment. Ehave's mental health informatics platform facilitates objective, data-driven decision making while keeping patients informed and engaged throughout their mental healthcare journey. Ehave offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems ("MHS"), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder ("ADHD"), through its collaboration with the Hospital for Sick Children ("SickKids"). Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with MedReleaf. For more information, visit https://www.ehave.com/.
Ehave Contacts
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)
(212) 375-2664
[email protected]
Janine McCargo (Media)
646-604-5150
[email protected]
SOURCE Ehave, Inc.
Share this article